DexCom Inc Cash Flow Conversion Efficiency
DexCom Inc cash flow conversion efficiency. Based on the latest financial reports, DexCom Inc (DXCM) has a cash flow conversion efficiency ratio of 0.178x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($525.60 Million) by net assets ($2.96 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of DexCom Inc (2003–2025)
Cash flow conversion efficiency of DexCom Inc from 2003 to 2025. This chart illustrates how DexCom Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DexCom Inc stock quote for real-time trading data and today's change.
DexCom Inc Cash Flow Conversion Ratio Explained
DexCom Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DexCom Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DexCom Inc ranked by their cash flow conversion efficiency. Also see DXCM company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KONE Oyj
HE:KNEBV
|
0.129x |
|
Sandoz Group AG
SW:SDZ
|
0.094x |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.208x |
|
Atmos Energy Corporation
NYSE:ATO
|
0.025x |
|
Jabil Circuit Inc
NYSE:JBL
|
0.403x |
|
Heidelberg Materials AG
XETRA:HEI
|
0.169x |
|
Banco Bradesco S.A
F:BREC
|
-0.288x |
|
TDK Corporation
F:TDKA
|
0.059x |
Annual Cash Flow Conversion Efficiency for DexCom Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of DexCom Inc from 2003 to 2025. Review DXCM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.75 Billion | $1.44 Billion | 0.525x | +11.48% |
| 2024-12-31 | $2.10 Billion | $989.50 Million | 0.471x | +30.06% |
| 2023-12-31 | $2.07 Billion | $748.50 Million | 0.362x | +15.22% |
| 2022-12-31 | $2.13 Billion | $669.50 Million | 0.314x | +44.93% |
| 2021-12-31 | $2.04 Billion | $442.50 Million | 0.217x | -16.78% |
| 2020-12-31 | $1.83 Billion | $475.60 Million | 0.260x | -26.93% |
| 2019-12-31 | $882.60 Million | $314.50 Million | 0.356x | +91.85% |
| 2018-12-31 | $663.30 Million | $123.20 Million | 0.186x | -15.33% |
| 2017-12-31 | $419.40 Million | $92.00 Million | 0.219x | +10.77% |
| 2016-12-31 | $283.80 Million | $56.20 Million | 0.198x | -10.61% |
| 2015-12-31 | $221.20 Million | $49.00 Million | 0.222x | +31.60% |
| 2014-12-31 | $140.20 Million | $23.60 Million | 0.168x | +489.86% |
| 2013-12-31 | $84.10 Million | $2.40 Million | 0.029x | +106.64% |
| 2012-12-31 | $77.00 Million | $-33.10 Million | -0.430x | -49.10% |
| 2011-12-31 | $104.49 Million | $-30.13 Million | -0.288x | +58.79% |
| 2010-12-31 | $60.99 Million | $-42.68 Million | -0.700x | -132.76% |
| 2009-12-31 | $-18.45 Million | $-39.39 Million | 2.135x | +120.17% |
| 2008-12-31 | $-38.61 Million | $-37.45 Million | 0.970x | +120.78% |
| 2007-12-31 | $7.12 Million | $-33.21 Million | -4.667x | -506.45% |
| 2006-12-31 | $56.83 Million | $-43.73 Million | -0.770x | -68.61% |
| 2005-12-31 | $49.41 Million | $-22.55 Million | -0.456x | -281.09% |
| 2004-12-31 | $-49.31 Million | $-12.43 Million | 0.252x | -13.15% |
| 2003-12-31 | $-32.60 Million | $-9.46 Million | 0.290x | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more